Filing Details
- Accession Number:
- 0001209191-22-046896
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-19 17:30:07
- Reporting Period:
- 2022-07-01
- Accepted Time:
- 2022-08-19 17:30:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1087294 | Cumberland Pharmaceuticals Inc | CPIX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1632384 | C Joseph Galante | 2525 West End Avenue Suite 950 Nashville TN 37203 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-07-01 | 70 | $2.11 | 48,836 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-05 | 86 | $2.18 | 48,922 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-06 | 86 | $2.11 | 49,008 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-07 | 86 | $2.18 | 49,094 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-08 | 86 | $2.19 | 49,180 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-12 | 86 | $2.25 | 49,266 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-14 | 86 | $2.28 | 49,352 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-15 | 86 | $2.23 | 49,438 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-18 | 74 | $2.41 | 49,512 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-19 | 74 | $2.47 | 49,586 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-20 | 74 | $2.52 | 49,660 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-21 | 74 | $2.54 | 49,734 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-22 | 74 | $2.53 | 49,808 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-25 | 74 | $2.48 | 49,882 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-26 | 74 | $2.47 | 49,956 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-27 | 60 | $2.36 | 50,016 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-28 | 74 | $2.28 | 50,090 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-07-29 | 74 | $2.28 | 50,164 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-01 | 74 | $2.34 | 50,238 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-03 | 30 | $2.45 | 50,268 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-04 | 74 | $2.17 | 50,342 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-05 | 74 | $2.12 | 50,416 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-08 | 82 | $2.19 | 50,498 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-09 | 82 | $2.19 | 50,580 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-10 | 82 | $2.19 | 50,662 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-11 | 82 | $2.46 | 50,744 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-12 | 82 | $2.52 | 50,826 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-15 | 65 | $2.45 | 50,891 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.